← Evidence map

ArticleDer Internist2017

[Bezlotoxumab for the secondary prevention of Clostridium difficile infection : MODIFY I and MODIFY II studies].

C Lübbert et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2017

this papercites it

[Bezlotoxumab for the secondary prevention of Clostridium difficile infection : MODIFY I and MODIFY II studies]. | OpenQuestion